These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31005215)

  • 21. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mortality after radiotherapy or surgery in the treatment of early-stage non-small-cell lung cancer: a population-based data analysis in the clinical cancer registry of Brandenburg-Berlin.
    Müller JA; Vordermark D; Medenwald D
    Strahlenther Onkol; 2023 Jul; 199(7):658-667. PubMed ID: 36912978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.
    Timmerman RD; Paulus R; Pass HI; Gore EM; Edelman MJ; Galvin J; Straube WL; Nedzi LA; McGarry RC; Robinson CG; Schiff PB; Chang G; Loo BW; Bradley JD; Choy H
    JAMA Oncol; 2018 Sep; 4(9):1263-1266. PubMed ID: 29852037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes in stage I non-small cell lung cancer following the introduction of stereotactic body radiotherapy in Alberta - A population-based study.
    Liu HW; Gabos Z; Ghosh S; Roberts B; Lau H; Kerba M
    Radiother Oncol; 2015 Oct; 117(1):71-6. PubMed ID: 26349589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    Verma V; Schonewolf CA; Cushman TR; Post CM; Doms A; Berman AT; DeVries M; Katz SI; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):502-510. PubMed ID: 30111509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer.
    Cornwell LD; Echeverria AE; Samuelian J; Mayor J; Casal RF; Bakaeen FG; Omer S; Preventza O; Mai W; Chen G; Simpson KH; Moghanaki D; Zhu AW
    J Thorac Cardiovasc Surg; 2018 Jan; 155(1):395-402. PubMed ID: 28888379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy.
    Sebastian N; Wu T; Bazan J; Driscoll E; Willers H; Yegya-Raman N; Bond L; Dwivedi A; Mo X; Tan Y; Xu-Welliver M; Haglund K; Jabbour SK; Keane FK; Williams TM
    Radiother Oncol; 2019 May; 134():151-157. PubMed ID: 31005209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of endobronchial ultrasound-guided transbronchial needle aspiration in stereotactic body radiation therapy for non-small cell lung cancer.
    Hashimoto K; Daddi N; Giuliani M; Hope A; Le LW; Czarnecka K; Cypel M; Pierre A; de Perrot M; Darling G; Waddell TK; Keshavjee S; Yasufuku K
    Lung Cancer; 2018 Sep; 123():1-6. PubMed ID: 30089578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
    Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
    Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer.
    Rosen JE; Salazar MC; Wang Z; Yu JB; Decker RH; Kim AW; Detterbeck FC; Boffa DJ
    J Thorac Cardiovasc Surg; 2016 Jul; 152(1):44-54.e9. PubMed ID: 27131846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer.
    Sebastian NT; Merritt RE; Abdel-Rasoul M; Wu T; Bazan JG; Xu-Welliver M; Haglund K; D'Souza D; Kneuertz PJ; Williams TM
    Ann Thorac Surg; 2020 Sep; 110(3):998-1005. PubMed ID: 32353436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.
    Raghavan G; Shaverdian N; Chan S; Chu FI; Lee P
    Clin Lung Cancer; 2018 Sep; 19(5):e759-e766. PubMed ID: 29954680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure.
    Narita A; Takeda A; Eriguchi T; Saigusa Y; Sanuki N; Tsurugai Y; Enomoto T; Kuribayashi H; Mizuno T; Yashiro K; Hara Y; Kaneko T
    J Radiat Res; 2019 Oct; 60(5):639-649. PubMed ID: 31322665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Wang S; Zhang B; Qian J; Qiao R; Xu J; Zhang L; Zhao Y; Zhang Y; Wang R; Zhao R; Han B
    Lung Cancer; 2018 Nov; 125():245-252. PubMed ID: 30429028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments.
    Ostheimer C; Evers C; Palm F; Mikolajczyk R; Vordermark D; Medenwald D
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2813-2822. PubMed ID: 31492985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.